about
Prognostic significance of pleural fluid data in patients with malignant effusion.XELOX (capecitabine plus oxaliplatin) as first-line treatment for elderly patients over 70 years of age with advanced colorectal cancerAddition of bevacizumab to XELOX induction therapy plus concomitant capecitabine-based chemoradiotherapy in magnetic resonance imaging-defined poor-prognosis locally advanced rectal cancer: the AVACROSS studyCapecitabine and bevacizumab as first-line treatment in elderly patients with metastatic colorectal cancerFirst-line bevacizumab and capecitabine-oxaliplatin in elderly patients with mCRC: GEMCAD phase II BECOX study.Correlation of hypertension and proteinuria with outcome in elderly bevacizumab-treated patients with metastatic colorectal cancer.Accuracy of fluorodeoxyglucose-PET imaging for differentiating benign from malignant pleural effusions: a meta-analysis.Capecitabine and irinotecan with bevacizumab 2-weekly for metastatic colorectal cancer: the phase II AVAXIRI studyClinical guideline SEOM: hepatocellular carcinomaPhase II randomised trial of raltitrexed-oxaliplatin vs raltitrexed-irinotecan as first-line treatment in advanced colorectal cancer.Irinotecan plus raltitrexed as first-line treatment in advanced colorectal cancer: a phase II study.Identifying Thoracic Malignancies Through Pleural Fluid Biomarkers: A Predictive Multivariate Model.A critical review of HER2-positive gastric cancer evaluation and treatment: from trastuzumab, and beyond.Clinical features and survival of lung cancer patients with pleural effusions.A Review of Clinical Studies and Practical Guide for the Administration of Triplet Chemotherapy Regimens with Bevacizumab in First-line Metastatic Colorectal CancerMRI assessment and outcomes in patients receiving neoadjuvant chemotherapy only for primary rectal cancer: long-term results from the GEMCAD 0801 trial.Novel biomarkers in primary breast core biopsies to predict poor response to neoadjuvant chemotherapy and appearance of metastases.Dynamic soluble changes in sVEGFR1, HGF, and VEGF promote chemotherapy and bevacizumab resistance: A prospective translational study in the BECOX (GEMCAD 09-01) trial.Gemcitabine-erlotinib versus gemcitabine-erlotinib-capecitabine in the first-line treatment of patients with metastatic pancreatic cancer: Efficacy and safety results of a phase IIb randomised study from the Spanish TTD Collaborative Group.Chemoradiation, surgery and adjuvant chemotherapy versus induction chemotherapy followed by chemoradiation and surgery: long-term results of the Spanish GCR-3 phase II randomized trial†.Preoperative chemotherapy in patients with intermediate-risk rectal adenocarcinoma selected by high-resolution magnetic resonance imaging: the GEMCAD 0801 Phase II Multicenter Trial.Phase II study of bevacizumab, capecitabine, and oxaliplatin followed by bevacizumab plus erlotinib as first-line therapy in metastatic colorectal cancer.[Palliative sedation: Current situation and areas of improvement].[Solid neoplasms associated with multiple myeloma][Accuracy of pleural fluid cytology in malignant effusions]Randomised study of tegafur and oral leucovorin versus intravenous 5-fluorouracil and leucovorin in patients with advanced colorectal cancer.TTF-1 and napsin A on cell blocks and supernatants of pleural fluids for labeling malignant effusions.Level of HER2 gene amplification predicts response and overall survival in HER2-positive advanced gastric cancer treated with trastuzumab.Coexpression of p-IGF-1R and MMP-7 Modulates Panitumumab and Cetuximab Efficacy in RAS Wild-Type Metastatic Colorectal Cancer Patients.Clinical Impact of 18F-FDG-PET in the Suspicion of Recurrent Ovarian Carcinoma Based on Elevated Tumor Marker Serum LevelsHigh levels of tumor markers in pleural fluid correlate with poor survival in patients with adenocarcinomatous or squamous malignant effusionsOrbital Metastases from Transitional-Cell Cancer of the Urinary BladderPrognostic value of c-FLIPL/s, HIF-1α, and NF-κβ in stage II and III rectal cancer[Treatment with interferon of systemic Langerhans-cell histiocytosis in an adult][Thyroid metastasis as a form of presentation of renal cell carcinoma][Melanoma and hypopigmentation]Endobronchial metastatic disease: analysis of 32 cases[Multiple drug resistance: current concepts and future perspectives]Prognostic significance of DNA ploidy, S-phase fraction, and P-glycoprotein expression in colorectal cancerShould a cytologic study be ordered in transudative pleural effusions?
P50
Q31159010-9260FB79-3733-49A9-8405-ADA49FB192D8Q33370632-14435AA6-16D9-4CC9-BDFA-0A1B0CE3F034Q33394804-630DD850-DEA4-4593-AAD4-34CDC1C879F8Q33847848-BA1FA1EF-0CD0-4F63-ADB9-36D39F02F7DEQ33918152-30275209-1E0E-4F47-856A-E71EE5E51E9FQ34989562-371EF41C-B33D-497D-858E-19A0744245B4Q35238336-23E733C5-CC49-4FC0-A501-F268990F8101Q35580537-E2624513-76FC-4464-9213-BFB2C1DFE161Q36400259-12E747FB-5823-4BD2-BE9A-2309E49799FDQ36614956-F4A091CC-E7C8-441C-B4A7-9930529050CEQ36695043-E4B8E82E-85B0-4159-8AA1-311F52748644Q37207143-DCE1D28D-31D3-4893-8FD2-59F26B45E262Q38221411-083180DF-287C-4400-B4E5-4366348B6F47Q38364297-5E843B3B-DA10-4E55-8103-68244469F384Q38674714-CFADD9F6-422C-470D-BC9D-5B00EAEF5A52Q38692801-69B4AAFA-066D-467C-AC18-A95ED297861BQ38788733-2A26D1A6-3A70-4D26-9963-B9B706D63517Q40157506-23B084A7-75F6-46AE-A17F-FD8FE1FCA3B3Q40325645-B41EBFDB-9F8A-4D22-B9D4-9052C010667AQ41751293-E9B040F8-4D92-4180-A75C-01E4BF06D24DQ42062093-D9BC337A-1AEA-42CB-B611-F7615E30DD71Q43654264-EB917953-D710-47FC-B6FB-8570F4BC5F1AQ43755958-1225CF50-388F-4CD9-8334-F596BF920121Q43917174-B97DE6E4-F905-4755-A2C7-86CCD78A5755Q46499394-17E3E8D8-9497-406D-84BF-BA958FBAE230Q46743284-488A7928-2EBD-4677-8546-3D3CA7D7B524Q53545078-5E2CF126-6F3E-474E-AB38-B30DE38AEE65Q54402875-DDE595A1-053C-4DB6-9D07-041D7A6F71B5Q55518473-9DBA98AF-EF02-48B3-904C-D7578B86F72EQ57219558-D849016E-67DE-4061-A8FE-D6F7D9D74BEAQ57531305-738A2A60-2DB5-4728-AD76-9E2A2AAE3B34Q59274627-EA23AF4D-0494-4FC8-94DC-36C08B05805FQ62338350-EF80AA4B-1E69-47D2-9F5C-DFD05B83A780Q68753020-DE74D2EA-CE28-4CA6-9E0D-3F5DA3E076A8Q70180749-7A94F7A8-CA9B-4869-B071-FEBB64C2C212Q70758855-8E01EB16-B419-4F3B-875A-B8E9AF3715ECQ71219492-36B630AB-D08B-442A-AEB7-894372BA1356Q72222833-7C63D502-8A7D-4EB1-89DB-E500B867B8B1Q73184474-FC78FAD8-0D82-42C6-80D2-C0CA4B68AC28Q73263259-CA1ABE16-A812-481B-9A00-898330268428
P50
description
Forscher
@de
chercheur
@fr
investigador
@es
researcher
@en
ricercatore
@it
wetenschapper
@nl
研究者
@zh
name
Antonia Salud
@en
Salud A
@ast
Salud A
@es
Salud A
@nl
type
label
Antonia Salud
@en
Salud A
@ast
Salud A
@es
Salud A
@nl
altLabel
Salud A
@en
prefLabel
Antonia Salud
@en
Salud A
@ast
Salud A
@es
Salud A
@nl
P108
P31
P496
0000-0002-7399-7484